Avalo Therapeutics (AVTX) Competitors $8.91 -0.17 (-1.87%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVTX vs. CYRX, NGNE, PROC, BTMD, DSGN, VYGR, CTNM, SLRN, KMDA, and CGCShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Cryoport (CYRX), Neurogene (NGNE), Procaps Group (PROC), biote (BTMD), Design Therapeutics (DSGN), Voyager Therapeutics (VYGR), Contineum Therapeutics (CTNM), Acelyrin (SLRN), Kamada (KMDA), and Canopy Growth (CGC). These companies are all part of the "pharmaceutical products" industry. Avalo Therapeutics vs. Cryoport Neurogene Procaps Group biote Design Therapeutics Voyager Therapeutics Contineum Therapeutics Acelyrin Kamada Canopy Growth Avalo Therapeutics (NASDAQ:AVTX) and Cryoport (NASDAQ:CYRX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, earnings, profitability, media sentiment, institutional ownership, risk, community ranking and dividends. Which has more volatility and risk, AVTX or CYRX? Avalo Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, Cryoport has a beta of 1.62, meaning that its share price is 62% more volatile than the S&P 500. Which has better earnings and valuation, AVTX or CYRX? Avalo Therapeutics has higher earnings, but lower revenue than Cryoport. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAvalo Therapeutics$820K112.94-$31.54MN/AN/ACryoport$226.11M1.72-$99.59M-$3.38-2.33 Do insiders & institutionals have more ownership in AVTX or CYRX? 87.1% of Avalo Therapeutics shares are held by institutional investors. Comparatively, 92.9% of Cryoport shares are held by institutional investors. 0.3% of Avalo Therapeutics shares are held by company insiders. Comparatively, 10.1% of Cryoport shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to AVTX or CYRX? In the previous week, Avalo Therapeutics had 2 more articles in the media than Cryoport. MarketBeat recorded 5 mentions for Avalo Therapeutics and 3 mentions for Cryoport. Cryoport's average media sentiment score of 0.97 beat Avalo Therapeutics' score of 0.20 indicating that Cryoport is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Avalo Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cryoport 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is AVTX or CYRX more profitable? Avalo Therapeutics has a net margin of 0.00% compared to Cryoport's net margin of -70.08%. Cryoport's return on equity of -13.35% beat Avalo Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Avalo TherapeuticsN/A -442.16% 122.99% Cryoport -70.08%-13.35%-6.43% Does the MarketBeat Community believe in AVTX or CYRX? Cryoport received 236 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 65.05% of users gave Cryoport an outperform vote while only 33.33% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformAvalo TherapeuticsOutperform Votes633.33% Underperform Votes1266.67% CryoportOutperform Votes24265.05% Underperform Votes13034.95% Do analysts rate AVTX or CYRX? Avalo Therapeutics presently has a consensus price target of $40.00, suggesting a potential upside of 348.93%. Cryoport has a consensus price target of $12.29, suggesting a potential upside of 56.31%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Avalo Therapeutics is more favorable than Cryoport.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67Cryoport 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.57 SummaryCryoport beats Avalo Therapeutics on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.I urge you to watch it now. Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$92.61M$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E RatioN/A10.5989.9717.18Price / Sales112.94195.801,116.21116.99Price / CashN/A57.1642.8937.86Price / Book0.985.094.784.78Net Income-$31.54M$151.83M$120.23M$225.60M7 Day Performance-3.47%-2.13%-1.92%-1.23%1 Month Performance-7.67%-3.10%11.49%3.36%1 Year Performance-25.75%11.54%30.57%16.60% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics3.7075 of 5 stars$8.91-1.9%$40.00+348.9%-13.7%$92.61M$820,000.000.0040Analyst ForecastNews CoverageHigh Trading VolumeCYRXCryoport3.0208 of 5 stars$7.65-0.5%$12.50+63.4%-49.8%$378.15M$226.11M-2.321,170Analyst ForecastGap DownNGNENeurogene3.7408 of 5 stars$24.70+5.1%$60.83+146.3%N/A$366.92M$925,000.000.0090PROCProcaps Group0.8826 of 5 stars$3.23+34.0%N/A-20.3%$364.41M$414.10M5.105,500News CoverageHigh Trading VolumeBTMDbiote3.0893 of 5 stars$6.60+3.6%$9.11+38.0%+20.8%$358.62M$193.06M24.77194Positive NewsGap UpDSGNDesign Therapeutics0.9221 of 5 stars$6.29+12.3%$7.00+11.3%+143.2%$356.15MN/A-7.1840News CoveragePositive NewsVYGRVoyager Therapeutics4.6114 of 5 stars$6.51+3.8%$17.00+161.1%-27.6%$355.64M$250.01M8.83100CTNMContineum Therapeutics1.9558 of 5 stars$13.68-2.5%$29.25+113.8%N/A$352.67M$50M0.0031News CoverageSLRNAcelyrin2.7884 of 5 stars$3.38+4.6%$11.75+247.6%-55.8%$339.12MN/A-1.31135KMDAKamada3.8909 of 5 stars$5.85-0.3%$14.50+147.9%-1.2%$336.26M$158.38M20.96360Positive NewsCGCCanopy Growth2.4368 of 5 stars$3.05-1.9%$3.50+14.8%-41.0%$332.27M$220.27M-0.631,029Analyst RevisionNews Coverage Related Companies and Tools Related Companies Cryoport Competitors Neurogene Competitors Procaps Group Competitors biote Competitors Design Therapeutics Competitors Voyager Therapeutics Competitors Contineum Therapeutics Competitors Acelyrin Competitors Kamada Competitors Canopy Growth Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTX) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
